10-K.Info (Beta Test) Courtesy of Short Sands, LLC | ||||||||||||||
| ||||||||||||||
|
10-K.Info (Beta Test) Courtesy of Short Sands, LLC | |||
ELEVANCE HEALTH, INC. | |||
Ticker: ELV Fiscal Year: 2009 | |||
Statement Of Cash Flows Indirect Investment Based Operations | |||
Period Ending Dec 31, 2009 10-K (Filed: Feb 18, 2010) | |||
| (In Thousands, except shares in actual) | |||
| 12 Months Ended | 12 Months Ended | 12 Months Ended | |
| Dec 31, 2009 | Dec 31, 2008 | Dec 31, 2007 | |
| Operating activities | |||
| Net income | $ 4,745,900 | 2,490,700 | 3,345,400 |
| Adjustments to reconcile net income to net cash provided by operating activities: | |||
| Net realized gains on investments | (56,400) | (28,700) | (270,900) |
| Other-than-temporary impairment losses recognized in income | 450,200 | 1,207,900 | 259,700 |
| Loss on disposal of assets | 16,400 | 7,200 | 11,300 |
| Gain on sale of business | (3,792,300) | 0 | 0 |
| Deferred income taxes | 61,300 | (481,400) | (105,500) |
| Amortization, net of accretion | 446,400 | 466,300 | 466,000 |
| Depreciation expense | 107,100 | 105,400 | 120,200 |
| Impairment of goodwill and other intangible assets | 262,500 | 141,400 | 0 |
| Share-based compensation | 153,600 | 156,000 | 177,100 |
| Excess tax benefits from share-based compensation | (9,600) | (16,000) | (153,300) |
| Changes in operating assets and liabilities, net of effect of business combinations and divestitures: | |||
| Receivables, net | (484,200) | (558,700) | (448,600) |
| Other invested assets, current | (62,500) | 103,300 | (3,000) |
| Other assets | (119,300) | (340,200) | 174,400 |
| Policy liabilities | (748,200) | 194,900 | 257,700 |
| Unearned income | (27,300) | (26,700) | 125,500 |
| Accounts payable and accrued expenses | 952,800 | (106,300) | (235,200) |
| Other liabilities | (248,800) | (797,000) | 176,500 |
| Income taxes | 1,391,400 | (47,300) | 447,300 |
| Other, net | (100) | 64,600 | 0 |
| Net cash provided by operating activities | 3,038,900 | 2,535,400 | 4,344,600 |
| Investing activities | |||
| Purchases of fixed maturity securities | (7,186,800) | (5,691,200) | (8,512,000) |
| Proceeds from fixed maturity securities: | |||
| Sales | 4,096,600 | 5,194,900 | 6,709,000 |
| Maturities, calls and redemptions | 1,551,700 | 1,669,600 | 1,618,400 |
| Purchases of equity securities | (318,900) | (1,327,500) | (1,389,200) |
| Proceeds from sales of equity securities | 577,300 | 1,083,100 | 1,411,700 |
| Purchases of other invested assets | (49,000) | (145,000) | (102,400) |
| Proceeds from sales of other invested assets | 3,500 | 32,800 | 10,400 |
| Changes in securities lending collateral | 132,400 | 325,100 | 50,600 |
| Purchases of subsidiaries, net of cash acquired | (66,300) | (197,700) | (298,500) |
| Proceeds from sales of subsidiaries, net of cash sold | 4,672,300 | 5,000 | 0 |
| Purchases of property and equipment | (378,400) | (345,600) | (322,000) |
| Proceeds from sale of property and equipment | 400 | 12,700 | 57,300 |
| Other, net | (32,000) | 0 | (2,200) |
| Net cash provided by (used in) investing activities | 3,002,800 | 616,200 | (768,900) |
| Financing activities | |||
| Net (repayments of) proceeds from commercial paper borrowings | (397,000) | (900,600) | 502,800 |
| Proceeds from long-term borrowings | 990,300 | 525,000 | 1,978,300 |
| Net (repayments of) proceeds from short-term borrowings | (98,000) | 98,000 | 0 |
| Repayment of long-term borrowings | (919,300) | (38,700) | (509,700) |
| Changes in securities lending payable | (132,400) | (325,100) | (50,600) |
| Changes in bank overdrafts | (344,100) | 44,800 | (117,100) |
| Repurchase and retirement of common stock | (2,638,400) | (3,276,200) | (6,151,400) |
| Proceeds from exercise of employee stock options and employee stock purchase plan | 126,500 | 121,200 | 784,500 |
| Excess tax benefits from share-based compensation | 9,600 | 16,000 | 153,300 |
| Net cash used in financing activities | (3,402,800) | (3,735,600) | (3,409,900) |
| Effect of foreign exchange rates on cash and cash equivalents | (6,700) | 0 | 0 |
| Change in cash and cash equivalents | 2,632,200 | (584,000) | 165,800 |
| Cash and cash equivalents at beginning of year | 2,183,900 | 2,767,900 | |
| Cash and cash equivalents at end of year | 4,816,100 | 2,183,900 | 2,767,900 |
| External Links | |
| ELEVANCE HEALTH, INC. (ELV) Fiscal Year 2009 | |
| Statements of 10-K in Excel | https://www.sec.gov/.../Financial.xlxs |
| Complete 10-K in HTML | https://www.sec.gov/.../10-K.html |
| Complete 10-K in XBRL | https://www.sec.gov/.../10-K-xbrl.zip |